Abstract
Background Adenoid cystic carcinoma (ACC) of the head and neck is a rare but highly malignant tumor. Cancer-testis antigens (CTAs) represent an immunogenic family of cancer-specific proteins and thus represent an attractive target for immunotherapy. Methods Eighty-four cases of ACC were identified, the CTAs pan-Melanoma antigen (pan-MAGE; M3H67) and New York esophageal squamous cell carcinoma (NY-ESO-1; E978) were detected immunohistochemically (IHC) and correlated with clinical data. Results Expression of NY-ESO-1 was found in 48 of 84 patients (57.1%) and of pan-MAGE in 28 of 84 patients (31.2%). Median overall survival (OS) in NY-ESO-1 positive versus negative patients was 130.8 and 282.0 months (p =.223), respectively. OS in pan-MAGE positive versus negative patients was 105.3 and 190.5 months, respectively (p =.096). Patients expressing both NY-ESO-1 and pan-MAGE simultaneously had significantly reduced OS with a median of 90.5 months compared with 282.0 months in negative patients (p =.047). Conclusion A significant fraction of patients with ACC show expression of the CTAs NY-ESO-1 and/or pan-MAGE with promising immunotherapeutic implications.
Original language | English (US) |
---|---|
Pages (from-to) | 1008-1016 |
Number of pages | 9 |
Journal | Head and Neck |
Volume | 38 |
Issue number | 7 |
DOIs | |
State | Published - Jul 1 2016 |
Externally published | Yes |
Keywords
- Melanoma antigen
- New York esophageal squamous cell carcinoma (NY-ESO-1)
- adenoid cystic carcinoma
- cancer-testis antigens
- head and neck cancer
ASJC Scopus subject areas
- Otorhinolaryngology